Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody Journal Article


Author: Chapman, P. B.
Article Title: Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody
Abstract: GD3, a ganglioside expressed on tumors of neuroectodermal origin such as melanoma and small-cell lung carcinoma (SCLC), is an attractive vaccine target but is poorly immunogenic. Our group has pursued several strategies designed to immunize patients against GD3 including using BEC2, an anti-idiotypic monoclonal antibody that mimics GD3. Pilot trials in melanoma and SCLC indicate that BEC2 can induce an anti-GD3 antibody response in a subset of patients and also suggests that immunization with BEC2 is associated with improved survival. A phase III trial is underway in SCLC patients to determine the effects BEC2 on overall survival.
Keywords: cancer chemotherapy; cancer survival; protein expression; unclassified drug; clinical trial; review; nonhuman; drug targeting; cancer radiotherapy; antineoplastic agent; neoplasms; animals; bcg vaccine; cancer immunotherapy; melanoma; immune system; nerve tissue proteins; antineoplastic activity; drug effect; monoclonal antibody; survival time; lung small cell cancer; pilot study; immunogenicity; antibody response; cancer immunization; vaccination; ganglioside gd3; vaccine; antibody titer; keyhole limpet hemocyanin; carcinoma, small cell; qs 21; gangliosides; bcg vaccination; neuroectoderm; gd3 ganglioside; monoclonal antibody bec2; antibodies, anti-idiotypic; ether-a-go-go potassium channels; anti-idiotype; small-cell lung carcinoma; immunotherapy, active; antiidiotypic antibody; potassium channels, voltage-gated; humans; human; potassium channels; monoclonal antibody r24; ganglioside gd3 lactone
Journal Title: Current Opinion in Investigational Drugs
Volume: 4
Issue: 6
ISSN: 1472-4472
Publisher: Current Drugs Ltd  
Date Published: 2003-01-01
Start Page: 710
End Page: 715
Language: English
PUBMED: 12901230
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 25 September 2014 -- Source: Scopus
Citation Impact
MSK Authors
  1. Paul Chapman
    326 Chapman